Gut microbiota signatures associated with KRAS mutations in patients with colorectal cancer (CRC) have been identified by researchers. Their findings suggest that the gut microbes may serve as ...

Avutometinib and defactinib combination shows over one-year median PFS in recurrent LGSOC patients, with notable efficacy in KRAS-mutant and KRAS-wild-type populations. Verastem Oncology plans FDA ...

Role of trimodality therapy versus dual-modality in T3N0 rectal cancer patients. Background: Prior clinical data suggest a dose-related response to cmab when combined with irinotecan in pts with KRAS ...

Please provide your email address to receive an email when new articles are posted on . Perioperative complication rates were similar between simultaneous and delayed resection of liver metastasis and ...

Although all authors completed the disclosure declaration, the following author(s) and/or an author's immediate family member(s) indicated a financial or other interest that is relevant to the subject ...

Researchers from Boehringer Ingelheim Pharma GmbH & Co KG have published preclinical data for their novel pan-KRAS inhibitors BI-2493 and BI-2865, both being developed for the treatment of cancer.

The FDA approved Avmapki Fakzynja Co-pack for KRAS-mutated, recurrent, low-grade serous ovarian cancer after prior systemic therapy. The RAMP-201 trial showed a 44% response rate, with response ...

Blood-based circulating tumor DNA (ctDNA) testing has proven to be insufficient for detecting KRAS mutations in patients with low-grade serous ovarian cancer (LGSOC), according to a study. The ...

Erica C. Nakajima, MD, discussed a pooled analysis analyzing immune checkpoint inhibitors with or without chemotherapy in the frontline treatment of patients with KRAS-mutated non-small cell lung ...